The Government today (December 20) said that a total of three types of COVID-19 vaccines (Comirnaty ancestral strain vaccine (30 micrograms/dose), Comirnaty bivalent vaccine and CoronaVac vaccine), which are currently supplied in Hong Kong by two drug manufacturers, namely Fosun Pharma and Sinovac, have been registered as pharmaceutical products in Hong Kong in accordance with the Pharmacy and Poisons Regulations (Cap. 138A).

     ​According to the Pharmacy and Poisons Regulations (Cap. 138A), pharmaceutical products (including vaccines) must satisfy the criteria of safety, efficacy and quality for registration with the Pharmacy and Poisons Board of Hong Kong (the Board) before they can be sold or supplied in Hong Kong. Upon submission of application and the relevant documentation required from applicants of registration, the Board will evaluate the registration application in accordance with established procedures and requirements. Comirnaty vaccines (ancestral strain vaccine (30 micrograms/dose) and bivalent vaccine) and CoronaVac (ancestral strain vaccine) have satisfied the criteria of safety, efficacy and quality, and the Board has issued the Certificates of Drug Registration to Fosun Pharma and Sinovac with regard to the relevant vaccines.

Ends/Tuesday, December 20, 2022
Issued at HKT 18:30

NNNN